Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Pharmacol. 2006 May;148(2):123-35.

Cannabinoids and cancer: pros and cons of an antitumour strategy.

Author information

  • 1Dipartimento di Scienze Farmaceutiche, Universit√† degli Studi di Salerno, Via Ponte Don Melillo, Fisciano 84084, Salerno, Italy. maubiful@unina.it

Abstract

In the last two decades, research has dramatically increased the knowledge of cannabinoids biology and pharmacology. In mammals, compounds with properties similar to active components of Cannabis sativa, the so called 'endocannabinoids', have been shown to modulate key cell-signalling pathways involved in cancer cell growth, invasion and metastasis. To date, cannabinoids have been licensed for clinical use as palliative treatment of chemotherapy, but increased evidences showed direct antiproliferative actions of cannabinoid agonists on several tumour cells in vitro and in animal models. In this article, we will review the principal molecular pathways modulated by cannabinoids on cancer and summarize pros and cons evidence on the possible future use of endocannabinoid-based drugs in cancer therapy.

PMID:
16501583
[PubMed - indexed for MEDLINE]
PMCID:
PMC1617062
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk